NFE2L2 and chronic myelogenous leukemia, BCR-ABL1 positive: Silencing of Nrf2 sensitizes the CML imatinib-resistant cells, ovarian cisplatin-resistant cancer cells, and lung doxorubicin-resistant cancer cells (Cho et al., 2008; Xu et al., 2019).